Back to Search Start Over

Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI.

Authors :
Streibel C
Willers CC
Pusterla O
Bauman G
Stranzinger E
Brabandt B
Bieri O
Curdy M
Bullo M
Frauchiger BS
Korten I
Krüger L
Casaulta C
Ratjen F
Latzin P
Kieninger E
Source :
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2023 Jul; Vol. 22 (4), pp. 615-622. Date of Electronic Publication: 2023 Jan 10.
Publication Year :
2023

Abstract

Background: With improvement in supportive therapies and the introduction of cystic fibrosis transmembrane conductance regulator (CFTR)-modulator treatment in patients with cystic fibrosis (CF), milder disease courses are expected. Therefore, sensitive parameters are needed to monitor disease course and effects of CFTR-modulators. Functional lung MRI using matrix-pencil decomposition (MP-MRI) is a promising tool for assessing ventilation and perfusion quantitatively. This study aimed to assess the treatment effect of elexacaftor/tezacaftor/ivacaftor combination regimen (ELX/TEZ/IVA) on measures of structural and functional lung abnormalities.<br />Methods: 24 children with CF underwent lung function tests (multiple breath washout, spirometry), functional and structural MRI twice (one year apart) before and once after at least two weeks (mean 4.7 ± 2.6 months) on ELX/TEZ/IVA. Main outcomes were changes (Δ) upon ELX/TEZ/IVA in lung function, defect percentage of ventilation (VDP) and perfusion (QDP), defect distribution index of ventilation and perfusion (DDI <subscript>V,</subscript> DDI <subscript>Q</subscript> ), and Eichinger score. Statistical analyses were performed using paired t-tests and multilevel regression models with bootstrapping.<br />Results: We observed a significant improvement in lung function, structural and functional MRI parameters upon ELX/TEZ/IVA treatment (mean; 95%-CI): ΔLCI <subscript>2.5</subscript> (TO) -0.84 (-1.62 to -0.06); ΔFEV <subscript>1</subscript> (z-score) 1.05 (0.56 to 1.55); ΔVDP (% of impairment) -6.00 (-8.44 to -3.55); ΔQDP (% of impairment) -3.90 (-5.90 to -1.90); ΔDDI <subscript>V</subscript> -1.38 (-2.22 to -0.53); ΔDDI <subscript>Q</subscript> -0.31 (-0.73 to 0.12); ΔEichinger score -3.89 (-5.05 to -2.72).<br />Conclusions: Besides lung function tests, functional and structural MRI is a suitable tool to monitor treatment response of ELX/TEZ/IVA therapy, and seems promising as outcome marker in the future.<br /> (Copyright © 2022. Published by Elsevier B.V.)

Details

Language :
English
ISSN :
1873-5010
Volume :
22
Issue :
4
Database :
MEDLINE
Journal :
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Publication Type :
Academic Journal
Accession number :
36635199
Full Text :
https://doi.org/10.1016/j.jcf.2022.12.012